Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer

Ya Gao; Shuzhen Shi; Ming Liu; Fanqi Wu; Junhua Zhang; Fujian Song; Jinhui Tian

doi:10.1002/14651858.CD014809

Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer

Ya Gao
, Shuzhen Shi
, Ming Liu
, Fanqi Wu
, Junhua Zhang
, Fujian Song
, Jinhui Tian

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

14 Downloads (Pure)

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To evaluate the efficacy and safety of immune checkpoint inhibitors (anti PD-1 or anti PD-L1) plus platinum-etoposide compared with platinum-etoposide alone for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).

Original language	English
Article number	CD014809
Journal	Cochrane Database of Systematic Reviews
Volume	2021
Issue number	10
DOIs	https://doi.org/10.1002/14651858.CD014809
Publication status	Published - 19 Oct 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1002/14651858.CD014809

Published_VersionFinal published version, 193 KB

Cite this

@article{78f23021a1094437b229ede10cf469a9,

title = "Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer",

abstract = "Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To evaluate the efficacy and safety of immune checkpoint inhibitors (anti PD-1 or anti PD-L1) plus platinum-etoposide compared with platinum-etoposide alone for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).",

author = "Ya Gao and Shuzhen Shi and Ming Liu and Fanqi Wu and Junhua Zhang and Fujian Song and Jinhui Tian",

year = "2021",

month = oct,

day = "19",

doi = "10.1002/14651858.CD014809",

language = "English",

volume = "2021",

journal = "Cochrane Database of Systematic Reviews",

issn = "1361-6137",

publisher = "Wiley",

number = "10",

}

Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer. / Gao, Ya; Shi, Shuzhen; Liu, Ming et al.
In: Cochrane Database of Systematic Reviews, Vol. 2021, No. 10, CD014809, 19.10.2021.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer

AU - Gao, Ya

AU - Shi, Shuzhen

AU - Liu, Ming

AU - Wu, Fanqi

AU - Zhang, Junhua

AU - Song, Fujian

AU - Tian, Jinhui

PY - 2021/10/19

Y1 - 2021/10/19

N2 - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To evaluate the efficacy and safety of immune checkpoint inhibitors (anti PD-1 or anti PD-L1) plus platinum-etoposide compared with platinum-etoposide alone for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).

AB - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To evaluate the efficacy and safety of immune checkpoint inhibitors (anti PD-1 or anti PD-L1) plus platinum-etoposide compared with platinum-etoposide alone for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).

UR - https://www.scopus.com/pages/publications/85117330320

U2 - 10.1002/14651858.CD014809

DO - 10.1002/14651858.CD014809

M3 - Article

SN - 1361-6137

VL - 2021

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 10

M1 - CD014809

ER -

Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer

Abstract

UN SDGs

Access to Document

Other files and links

Cite this